Evitria AG

https://www.evitria.com

LinkedIn: https://www.linkedin.com/company/evitria-ag

evitria AG is the market-leading transient CHO expression service provider. Based in Zurich, Switzerland, they have supported a global base of preclinical researchers with CHO-based transient expression for over 12 years. With a track record of more than 100,000 transfections and more than 15,000 antibodies and proteins purified, evitria has fully optimized their workflows for high quality productions in the shortest timeframes possible. *

	Start	2010-01-01 established
	Group	Atlas Antibodies (Group)
	Industry	CHO cell line
	Industry 2	recombinant protein production in mammalian cells
	Person	Eberle, Christian (Evitria 202107 CEO)
	Person 2	Schofield, Desmond (Evitria 202107 Director of Business Development)

	Region	Schlieren ZH
	Country	Switzerland
	Street	25 Wagistr. Bio-Technopark
	City	8952 Schlieren ZH
	Tel	+41-43-539-8815
		Address record changed: 2022-08-11

Basic data	Employees	n. a.

		* Document for »About Section«: Evitria AG. (8/8/22). "Press Release: Genovis AB Enters Service Agreement with Evitria AG for Fast LC-MS Analysis of Recombinant Antibodies".

		Record changed: 2023-07-10

Picture Berlin Partner BIO 2024 International Convention San Diego 650x200px

More documents for Atlas Antibodies (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]